SuperworthDocGo PE ratio DCGO
Share price divided by earnings per share over the last twelve months, since 2023.
- Today, Oct 23, 2026
- n/m
- losses over the last year
- Last meaningful
- 12.8×
- May 2025
- 4-year median
- 25.6×
- 4-year range
- 11.6× to 125×
- Peer median
- 12.8×
DocGo has no meaningful PE ratio today: it lost $1.96 a share over the last twelve months, and a PE needs earnings.
It was last meaningful in May 2025, at 12.8×.
On the days it had one over the last 4 years, its median was 25.6×, from 11.6× in Oct 2024 to 125× in Aug 2023.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 12.8× | 11.8× | 19.8× |
| 2024 | 15.6× | 11.6× | 59.0× |
| 2023 | 55.9× | 23.5× | 125× |
Against its peers
Companies in Healthcare nearest DocGo's size, closest first, today.
| Company | PE ratio |
|---|---|
| DCGODocGo | n/m |
| NEPHNephros | 22.1× |
| ATNMActinium Pharmaceuticals | 4.2× |
| APTAlpha Pro Tech | 13.6× |
| SPROSpero Therapeutics | 10.1× |
| LFVNLifevantage | 14.7× |
| ICCCImmucell | 128× |
| KEQUKewaunee Scientific | 11.9× |
| PDEXPro DEX | 15.1× |
| PLXProtalix BioTherapeutics | 11.1× |
| NATRNatures Sunshine Products | 12.0× |
| Peer median | 12.8× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on DocGo
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.